Wellcebro-FM Tablet SR is a sustained-release formulation combining Montelukast (10mg), Fexofenadine (120mg), and Acebrophylline (200mg), designed for the effective management of respiratory conditions characterized by bronchoconstriction, allergic rhinitis, and chronic obstructive pulmonary disease (COPD). Montelukast, a leukotriene receptor antagonist, helps reduce airway inflammation and bronchospasm by blocking leukotriene receptors, thereby improving respiratory function and reducing asthma symptoms. Fexofenadine, a second-generation antihistamine, selectively inhibits peripheral H1 receptors, providing relief from allergic symptoms such as sneezing, nasal congestion, and urticaria without causing significant sedation. Acebrophylline acts as a bronchodilator and mucolytic agent, facilitating airway clearance and improving airflow by relaxing bronchial smooth muscles and reducing mucus viscosity. The combination of these active ingredients offers a comprehensive therapeutic approach by addressing inflammation, allergic response, and bronchial obstruction simultaneously. Wellcebro-FM Tablet SR is indicated for the treatment of asthma, allergic rhinitis, and COPD, promoting improved respiratory function and enhanced patient compliance due to its sustained-release formulation. It should be used under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Contraindications include hypersensitivity to any component and caution in patients with hepatic or renal impairment.